Publication date: Aug 31, 2024
Lung cancer and tuberculosis share similar risk factors, clinical spectrum, radiological features and it is difficult to differentiate but it is important to diagnose both conditions for targeted therapy and better outcome. Our primary objective was to estimate the proportion of TB in primary biopsy proven non-small cell lung carcinoma (NSCLC) cases. This prospective observational study was conducted in the Departments of Medicine/ Pulmonary Medicine/Medical Oncology and Microbiology at the All India Institute of Medical Sciences, New Delhi for a period of 2 years (January, 2020-December, 2021). Patients with biopsy proven, primary non-small cell lung cancer were recruited and sputum samples were subjected to microbiological investigations to confirm tuberculosis. Comparison was done in two groups of lung cancer patients with confirmed TB (Group A) and without confirmed tuberculosis (Group B). Total 75 patients with biopsy proven, primary NSCLC were recruited and 16% (12/75) were diagnosed with confirmed TB. Adenocarcinoma (36. 48%) and Squamous cell carcinoma (33. 44%) were the two predominant histopathological subtypes of NSCLC. About 57 (76%) of them were found to be in stage IV of Lung cancer at initial presentation itself (75% in group A & 74. 6 % in group B; p value
| Concepts | Keywords |
|---|---|
| Biopsy | Adenocarcinoma |
| Stage | Lung cancer |
| Tuberculosis | Mycobacterium tuberculosis |
| Pulmonary Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | non-small cell lung carcinoma |
| disease | MESH | Lung cancer |
| drug | DRUGBANK | Tropicamide |
| pathway | KEGG | Non-small cell lung cancer |
| disease | MESH | Adenocarcinoma |
| disease | MESH | Squamous cell carcinoma |
| disease | MESH | Pulmonary Tuberculosis |